Impact of Finasteride on Survival in Bladder Cancer: A Retrospective Multi-institutional Database Analysis

Garg, Harshit; Wheeler, Krista K.; Dursun, Furkan; Cooper, Robert E.; Pruthi, Deepak; Kaushik, Dharam; Thompson, Ian M.; Svatek, Robert S.; Liss, Michael A.

doi:10.1016/j.clgc.2022.10.014

Cited by 4 publications

(1 citation statement)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Gastric, pancreatic and bladder cancers are also shown to have no significant association with testosterone levels ( 81 ). Interestingly, androgen deprivation therapy (ADT) using finasteride has shown improved survival in patients with non-muscle invasive bladder cancer, suggesting a potential strategy to reduce bladder cancer incidence and recurrence ( 83 ).…”

Section: Androgens Ar and Tumour Pathophysiologymentioning

confidence: 99%

Sex differences in cancer and immunotherapy outcomes: the role of androgen receptor

Zhao,

Wang,

Tan

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

Across the wide range of clinical conditions, there exists a sex imbalance where biological females are more prone to autoimmune diseases and males to some cancers. These discrepancies are the combinatory consequence of lifestyle and environmental factors such as smoking, alcohol consumption, obesity, and oncogenic viruses, as well as other intrinsic biological traits including sex chromosomes and sex hormones. While the emergence of immuno-oncology (I/O) has revolutionised cancer care, the efficacy across multiple cancers may be limited because of a complex, dynamic interplay between the tumour and its microenvironment (TME). Indeed, sex and gender can also influence the varying effectiveness of I/O. Androgen receptor (AR) plays an important role in tumorigenesis and in shaping the TME. Here, we lay out the epidemiological context of sex disparity in cancer and then review the current literature on how AR signalling contributes to such observation via altered tumour development and immunology. We offer insights into AR-mediated immunosuppressive mechanisms, with the hope of translating preclinical and clinical evidence in gender oncology into improved outcomes in personalised, I/O-based cancer care.

show abstract

Section: Androgens Ar and Tumour Pathophysiologymentioning

confidence: 99%